Resources

This case profile highlights a project in Tanzania as an example of PATH's efforts to deliver critical services while strengthening health systems. Key issues related to the delivery of integrated TB–HIV services in low-resource settings are summarized along with PATH’s efforts to deliver innovative service models, address human resource constraints, and improve management of these diseases in the region.

This case profile highlights a suite of supply-chain projects in reproductive health that serve as examples of PATH's efforts in strengthening health systems. Key issues related to the availability, affordability, and quality of reproductive health supplies are summarized along with PATH’s efforts to improve manufacturing, purchasing, and distribution of reproductive health supplies globally.

In 2006, the Global Campaign for Microbicides embarked on an exercise to map the standards of care and prevention provided to participants in late-stage microbicide trials. The resulting report provides an independent assessment of the health care and prevention services provided to women in the trials (and to some extent, their partners, family, and surrounding community), explores the factors that inform care-related decisions at trial sites, and offers recommendations to strengthen the HIV prevention research field’s ability to respond to care-related challenges in the future.

This paper was commissioned for the aids2031 Science and Technology Working Group as part of a series of working papers under the aids2031 initiative. In line with thinking about the future development of new tools for diagnosis of HIV infection, this paper presents an analysis of issues related to diagnostic tests for HIV case management and explores four possible scenarios in which these tests could be performed.

This paper was commissioned for the aids2031 Science and Technology Working Group as part of a series of working papers under the aids2031 initiative. This paper explores issues that could be included in a future research agenda to enhance drug development for HIV/AIDS, including the optimal time to begin antiretroviral therapy, appropriate dosing of antiretrovirals, possible implications of HIV on advanced aging, and an exploration of recent challenges in drug development.